GLPG1690 is the latest offering from Belgium-based clinical biotechnology company, Galapagos NV, which has pioneered novel approaches toward treating pulmonary and inflammatory diseases.
How GLPG1690 Works
GLPG1690 is unique in that it targets a novel molecule, GPR84, a pro-inflammatory protein responsible for chronic low grade inflammatory diseases. The mechanism of action was proven in a Phase 1 clinical trial conducted by the company, which yielded positive results in terms of efficacy, safety, and tolerability.
The study was a randomized, double-blind, placebo-controlled, single-center study conducted in 40 healthy volunteers in Belgium, with escalating oral doses. The first part of the study included single ascending doses and the second part involved administration of daily doses for 14 days.
Next Steps for GLPG1690
With favorable pharmacokinetic and pharmacodynamic properties of the drug, along with proper engagement with the target molecule evaluated with the help of a biomarker, Galapagos decided to proceed with a Phase 2 clinical trial to test the effectiveness of this oral formulation in patients with idiopathic pulmonary fibrosis (IPF).
In April 2016, Galapagos announced it started a Phase 2a study with GLPG1690 in IPF patients. The FLORA clinical trial is a randomized, double-blind, placebo-controlled study investigating a once-daily oral dose of GLPG1690 administered for 12 weeks in 24 patients. The primary endpoints are to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug candidate.
Note: Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.